~~<i id='5312767622'><strike id='5312767622'><tt id='5312767622'><pre id='5312767622'></pre></tt></strike></i>~~

Home» focus» hotspot

hotspot

author：Wikipedia 2025-09-30 02:50:43 Page View：2

A green number 3 with an eye is surrounded by smaller, black number 3s on a purple background — 3 to watch coverage from STAT — Christine Kao/STAT

Life in the CRISPR lane tends to move at lightning speed. This year saw the first-ever approval of a medicine based on the gene editing technology, barely more than a decade after publication of its first demonstration by Nobel laureates Jennifer Doudna and Emmanuelle Charpentier.

The landmark decision paves the way for in vivo therapies, which edit cells inside the body, to reach patients, as well as treatments based on more efficient genome editors with fancier DNA-altering tricks up their sleeves.

Here are three CRISPR developments we’re watching in 2024:

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Boston's new lab space is opening empty
Next article： Continuity nursing helped my family in our darkest PICU moments

leisure time

23andMe had bad news about my health. I wish a person had delivered it

ERICBARADAT/AFP/GettyImagesLastsummer,IthoughtitmightbefuntohavemyDNAanalyzed.Twocompanies,23andMean

AI can decode, harness the power of the humane immune system

AdobeIftheCovid-19pandemichasshownusonething,itishowlittlewereallyknowabouthowthehumanimmunesystemwo

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

EPA limits use of carcinogenic gas for sterilizing medical devices

TheagencyfirstproposedlimitsonthegasinApril2023,withthegoalofreducingemissionsby80%.Now,theagencyisp